|
Demographic data
|
|
Age (Median, Interquartile range)
|
52 (37.3–64.8)
|
51 (38–63)
|
0.908
|
|
Age ≥ 65 years
|
18 (25.0)
|
155 (20.2)
|
0.868
|
|
Male sex
|
58 (79.5)
|
500 (65.3)
|
0.098
|
|
Community-acquired diarrhea
|
15 (20.5)
|
168 (21.9)
|
0.980
|
|
Gastrointestinal disease
|
22 (30.1)
|
217 (28.3)
|
1.042
|
|
Hepatobiliary disease
|
6 (8.2)
|
65 (8.5)
|
1.026
|
|
Cardiovascular disease
|
6 (8.2)
|
51 (6.7)
|
0.910b
|
|
Kidney disease
|
9 (12.3)
|
13 (1.7)
|
< 0.001 ***
|
|
Hemopathy
|
4 (5.5)
|
36 (4.7)
|
1.038b
|
|
Malignancy
|
4 (5.5)
|
21 (2.7)
|
0.843b
|
|
Autoimmune disease
|
1 (1.4)
|
15 (2.0)
|
1.000b
|
|
Diabetes mellitus
|
5 (6.8)
|
44 (5.7)
|
0.922b
|
|
Presumed risk factors
|
|
Prior hospitalization
|
43 (58.9)
|
458 (59.8)
|
1.030
|
|
Antibiotic
|
53 (72.6)
|
380 (49.6)
|
0.003**
|
|
No. of antibiotics (≥3)
|
14 (19.2)
|
112 (14.6)
|
0.373
|
|
Aminoglycosides
|
2 (2.7)
|
10 (1.3)
|
0.401b
|
|
β-lactam/β-lactamase inhibitor combinations
|
34 (46.6)
|
165 (21.5)
|
< 0.001***
|
|
Carbapenems
|
17 (23.3)
|
127 (16.6)
|
0.365
|
|
3rd and 4th generation cephalosporins
|
3 (4.1)
|
10 (1.3)
|
0.320b
|
|
Fluoroquinolones
|
24 (32.9)
|
147 (19.2)
|
0.030*
|
|
Glycopeptide
|
6 (8.2)
|
38 (5.0)
|
0.440b
|
|
Tetracyclines
|
3 (4.1)
|
47 (6.1)
|
0.681b
|
|
Metronidazole
|
4 (5.5)
|
51 (6.7)
|
0.697b
|
|
Vancomycin
|
4 (5.5)
|
20 (2.6)
|
0.296b
|
|
Proton pump inhibitors
|
45 (61.6)
|
421 (55.0)
|
0.793
|
|
Nasogastric tube
|
11 (15.1)
|
89 (1.6)
|
0.842
|
|
Abdominal surgery
|
2 (2.7)
|
29 (3.8)
|
1.000b
|
|
Chemotherapy
|
2 (2.7)
|
37 (4.8)
|
0.947b
|
|
Immunosuppressive agents
|
2 (2.7)
|
10 (1.3)
|
0.757b
|
|
Biological parameters
|
|
WBC (×109/L)
|
6.5 (4.54–9.26)
|
6.23 (4.89–8.10)
|
1.034
|
|
WBC count > 9.5 × 109/L
|
17 (23.3)
|
152 (11.8)
|
0.939
|
|
NEU%
|
73.6 (64.9–81.4)
|
64.00 (56.5–75.7)
|
0.035*
|
|
Neutropenia (> 75%)
|
29 (39.7)
|
241 (31.5)
|
0.579
|
|
HB (g/L)
|
116 (92–128)
|
123.00 (108–135)
|
0.655
|
|
PLT (×109/)
|
204 (138--271)
|
192.00 (155–262)
|
0.933
|
|
ALB (g/L)
|
36 (30.1–41.1)
|
40.4 (35.3–42.4)
|
0.420
|
|
Hypoalbuminemia (< 35 g/L)
|
33 (45.2)
|
206 (26.9)
|
0.012*
|
|
AST (U/L)
|
19 (13–26)
|
18 (15–26)
|
0.999
|
|
CRE (umol/L)
|
73 (53–100)
|
65 (56–83)
|
0.728
|
|
Serum creatinine > 195 μmol/L
|
3 (4.1)
|
10 (1.3)
|
0.420b
|
|
hsCRP (mg/L)
|
11.1 (4.8–77.7)
|
4.6 (0.7–27.6)
|
0.426
|
|
Clinical symptoms
|
|
Abdominal pain
|
7 (9.6)
|
57 (7.4)
|
0.938
|
|
Fever
|
4 (5.5)
|
36 (4.7)
|
0.999b
|
|
Vomit
|
1 (1.4)
|
8 (1.0)
|
0.982
|
|
Hematochezia
|
6 (8.2)
|
57 (7.4)
|
0.978
|
